Foley & Lardner LLP partner Louis Lehot assessed the prospect of an incoming IPO resurgence in the Law360 article, “Fall IPO Pickup Could Be A Prelude For 2025 Recovery.”
“There is a strong backlog of companies that want to go,” Lehot emphasized. “But until you see interest rates cut and demand come up, it’s really hard to jump out there into the cold, freezing tundra.”
Lehot added that the price of bitcoin is also worth watching as a barometer of investors’ risk appetite, with a hearty appetite necessary to spur a broader IPO recovery. With Bitcoin trading up more than 50% year to date, Lehot said this could be promising for IPOs headed into 2025.
(Subscription required)
People
Related News
26 September 2024
In the News
Gregory Marino on NIL Litigation – 'Schools want to know where the line is, and now everything is in flux'
Foley & Lardner LLP special counsel Gregory Marino shared insight on the growing complexities of collegiate sports in the ABA Journal article, "Money and litigation tangle with recent rules for college athletes' NIL deals."
24 September 2024
In the News
Thomas Ferrante Assesses Recent HHS OIG Report on Remote Patient Monitoring
Foley & Lardner LLP partner Thomas Ferrante commented on the recently released report on remote patient monitoring from the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Fierce Healthcare article, “HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown.”
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."